This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kitakaze, M. Articles by Hori, M. Search for Related Content PubMed PubMed Citation Articles by Kitakaze, M. Articles by Hori, M. Related Collections Cardiovascular Pharmacology Cell signalling/signal transduction Ischemic biology - basic studies

(Circulation Research. 2000;87:303.)
© 2000 American Heart Association, Inc.

Integrative Physiology

Protein Tyrosine Kinase Is Not Involved in the Infarct Size–Limiting Effect of Ischemic Preconditioning in Canine Hearts

Masafumi Kitakaze, Koichi Node, Hiroshi Asanuma, Seiji Takashima, Yasuhiko Sakata, Masanori Asakura, Shoji Sanada, Yoshiro Shinozaki, Hidezo Mori, Tsunehiko Kuzuya, Masatsugu Hori

From the Department of Internal Medicine and Therapeutics (M.K., K.M., H.A., S.T., Y. Sakata, M.A., S.S., T.K., M.H.), Osaka University Graduate School of Medicine, Suita, and Department of Physiology (Y. Shinozaki, H.M.), Tokai University School of Medicine, Isehara, Japan.

Correspondence to Masafumi Kitakaze, MD, PhD, Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka Pref 565-0871, Japan. E-mail kitakaze{at}medone.med.osaka-u.ac.jp

Abstract—Protein kinase C (PKC) plays an important role in ischemic preconditioning (IP). Because (1) tyrosine kinase is located at the downstream of PKC for IP in the rabbit hearts and (2) we have reported that ecto–5'-nucleotidase is the substrate for PKC and plays a crucial role for the infarct size–limiting effect, we tested whether tyrosine kinase activation contributes to either activation of ecto–5'-nucleotidase or the infarct size–limiting effect of the early phase of IP in the canine heart. In dogs, the IP procedure (4 cycles of 5-minute occlusion of coronary artery) and exposure to 12,13-phorbol myristate acetate (PMA) each activated myocardial ecto–5'-nucleotidase and Lck tyrosine kinase. Genistein (10, 30, and 100 µg · kg^-1 · min^-1 IC), an inhibitor of tyrosine kinase, attenuated the activation of Lck tyrosine kinase but did not attenuate the activation of ecto–5'-nucleotidase due to either IP or PMA. In the other canine hearts, IP attenuated infarct size (49±5 versus 11±3 or 16±3%, P<0.01) due to 90 minutes of coronary occlusion followed by 6 hours of reperfusion, which was not blunted by 3 or 2 (30 and 100 µg · kg^-1 · min^-1) doses of genistein (infarct sizes, 15±4, 13±4, and 13±3%, respectively, and 17±3 and 15±4%, respectively) or lavendustin A. Tyrosine kinase does not activate ecto–5'-nucleotidase or trigger the infarct size–limiting effect of the early phase of IP in canine hearts.

Key Words: ischemic preconditioning • protein kinase C • genistein • lavendustin A

This article has been cited by other articles:

				V. Piriou, J. Mantz, G. Goldfarb, M. Kitakaze, P. Chiari, S. Paquin, C. Cornu, J.-B. Lecharny, P. Aussage, E. Vicaut, et al. Sevoflurane preconditioning at 1 MAC only provides limited protection in patients undergoing coronary artery bypass surgery: a randomized bi-centre trial Br. J. Anaesth., November 1, 2007; 99(5): 624 - 631. [Abstract] [Full Text] [PDF]

				R. Schulz A new paradigm: cross talk of protein kinases during reperfusion saves life! Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H1 - H2. [Full Text] [PDF]

				S. Sanada, H. Asanuma, O. Tsukamoto, T. Minamino, K. Node, S. Takashima, T. Fukushima, A. Ogai, Y. Shinozaki, M. Fujita, et al. Protein Kinase A as Another Mediator of Ischemic Preconditioning Independent of Protein Kinase C Circulation, July 6, 2004; 110(1): 51 - 57. [Abstract] [Full Text] [PDF]

				Y. Liao, S. Takashima, Y. Asano, M. Asakura, A. Ogai, Y. Shintani, T. Minamino, H. Asanuma, S. Sanada, J. Kim, et al. Activation of Adenosine A1 Receptor Attenuates Cardiac Hypertrophy and Prevents Heart Failure in Murine Left Ventricular Pressure-Overload Model Circ. Res., October 17, 2003; 93(8): 759 - 766. [Abstract] [Full Text] [PDF]

				G. Yamaura, T. Turoczi, F. Yamamoto, M. A. Q. Siddqui, N. Maulik, and D. K. Das STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H476 - H482. [Abstract] [Full Text] [PDF]

				B. Dawn, H. Takano, X.-L. Tang, E. Kodani, S. Banerjee, A. Rezazadeh, Y. Qiu, and R. Bolli Role of Src protein tyrosine kinases in late preconditioning against myocardial infarction Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H549 - H556. [Abstract] [Full Text] [PDF]

				R. Schulz, M. V Cohen, M. Behrends, J. M Downey, and G. Heusch Signal transduction of ischemic preconditioning Cardiovasc Res, November 1, 2001; 52(2): 181 - 198. [Full Text] [PDF]

				R. Hattori, H. Otani, T. Uchiyama, H. Imamura, J. Cui, N. Maulik, G. A. Cordis, L. Zhu, and D. K. Das Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1066 - H1074. [Abstract] [Full Text] [PDF]